A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen

Trial Profile

A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Apr 2011

At a glance

  • Drugs Entecavir; Lamivudine
  • Indications Hepatitis B
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 02 Oct 2010 Results will be presented at the 61st annual meeting of the American Association for the Study of Liver Diseases (AASLD), according to a Bristol-Myers Squibb media release.
    • 03 Nov 2008 Results from rollover study 901 reported at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), reported in a Bristol-Myers Squibb media release.
    • 09 Mar 2006 Results have been published.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top